Manus J Donahue1, Lindsey M Dethrage2, Carlos C Faraco2, Lori C Jordan2, Paul Clemmons2, Robert Singer2, J Mocco2, Yu Shyr2, Aditi Desai2, Anne O'Duffy2, Derek Riebau2, Lisa Hermann2, John Connors2, Howard Kirshner2, Megan K Strother2. 1. From the Departments of Radiology (M.J.D., L.M.D., C.C.F., A.D., J.C., M.K.S.), Neurology (M.J.D., L.C.J., P.C., A.O., D.R., L.H., H.K.), Psychiatry (M.J.D.), Physics (M.J.D.), and Neurosurgery (J.M., J.C., M.K.S.) and Center for Quantitative Sciences (Y.S.), Vanderbilt University, Nashville, TN; and Department of Neurosurgery, Geisel School of Medicine, Dartmouth College, Lebanon, NH (R.S.); mj.donahue@vanderbilt.edu. 2. From the Departments of Radiology (M.J.D., L.M.D., C.C.F., A.D., J.C., M.K.S.), Neurology (M.J.D., L.C.J., P.C., A.O., D.R., L.H., H.K.), Psychiatry (M.J.D.), Physics (M.J.D.), and Neurosurgery (J.M., J.C., M.K.S.) and Center for Quantitative Sciences (Y.S.), Vanderbilt University, Nashville, TN; and Department of Neurosurgery, Geisel School of Medicine, Dartmouth College, Lebanon, NH (R.S.);
Abstract
BACKGROUND AND PURPOSE: A promising method for identifying hemodynamic impairment that may serve as a biomarker for stroke risk in patients with intracranial stenosis is cerebrovascular reactivity (CVR) mapping using noninvasive MRI. Here, abilities to measure CVR safely in the clinic using hypercarbic hyperoxic (carbogen) gas challenges, which increase oxygen delivery to tissue, are investigated. METHODS: In sequence with structural and angiographic imaging, blood oxygenation level-dependent carbogen-induced CVR scans were performed in patients with symptomatic intracranial stenosis (n=92) and control (n=10) volunteers, with a subgroup of patients (n=57) undergoing cerebral blood flow-weighted pseudocontinuous arterial spin labeling CVR. Subjects were stratified for 4 substudies to evaluate relationships between (1) carbogen and hypercarbic normoxic CVR in healthy tissue (n=10), (2) carbogen cerebral blood flow CVR and blood oxygenation level-dependent CVR in intracranial stenosis patients (n=57), (3) carbogen CVR and clinical measures of disease in patients with asymmetrical intracranial atherosclerotic (n=31) and moyamoya (n=29) disease, and (4) the CVR scan and immediate and longer-term complications (n=92). RESULTS: Noninvasive blood oxygenation level-dependent carbogen-induced CVR values correlate with (1) lobar hypercarbic normoxic gas stimuli in healthy tissue (R=0.92; P<0.001), (2) carbogen-induced cerebral blood flow CVR in patients with intracranial stenosis (R=0.30-0.33; P<0.012), and (3) angiographic measures of disease severity both in atherosclerotic and moyamoya patients after appropriate processing. No immediate stroke-related complications were reported in response to carbogen administration; longer-term neurological events fell within the range for expected events in this patient population. CONCLUSIONS: Carbogen-induced CVR elicited no added adverse events and provided a surrogate marker of cerebrovascular reserve consistent with intracranial vasculopathy.
BACKGROUND AND PURPOSE: A promising method for identifying hemodynamic impairment that may serve as a biomarker for stroke risk in patients with intracranial stenosis is cerebrovascular reactivity (CVR) mapping using noninvasive MRI. Here, abilities to measure CVR safely in the clinic using hypercarbic hyperoxic (carbogen) gas challenges, which increase oxygen delivery to tissue, are investigated. METHODS: In sequence with structural and angiographic imaging, blood oxygenation level-dependent carbogen-induced CVR scans were performed in patients with symptomatic intracranial stenosis (n=92) and control (n=10) volunteers, with a subgroup of patients (n=57) undergoing cerebral blood flow-weighted pseudocontinuous arterial spin labeling CVR. Subjects were stratified for 4 substudies to evaluate relationships between (1) carbogen and hypercarbic normoxic CVR in healthy tissue (n=10), (2) carbogen cerebral blood flow CVR and blood oxygenation level-dependent CVR in intracranial stenosispatients (n=57), (3) carbogen CVR and clinical measures of disease in patients with asymmetrical intracranial atherosclerotic (n=31) and moyamoya (n=29) disease, and (4) the CVR scan and immediate and longer-term complications (n=92). RESULTS: Noninvasive blood oxygenation level-dependent carbogen-induced CVR values correlate with (1) lobar hypercarbic normoxic gas stimuli in healthy tissue (R=0.92; P<0.001), (2) carbogen-induced cerebral blood flow CVR in patients with intracranial stenosis (R=0.30-0.33; P<0.012), and (3) angiographic measures of disease severity both in atherosclerotic and moyamoya patients after appropriate processing. No immediate stroke-related complications were reported in response to carbogen administration; longer-term neurological events fell within the range for expected events in this patient population. CONCLUSIONS:Carbogen-induced CVR elicited no added adverse events and provided a surrogate marker of cerebrovascular reserve consistent with intracranial vasculopathy.
Authors: Marco Matteo Ciccone; Rakesh K Sharma; Pietro Scicchitano; Francesca Cortese; Christian Salerno; Paola Berchialla; Giulia Frasso; Marco Sassara; Mariangela Carbone; Pasquale Palmiero; Maria Maiello; Donald J Voelker; Hanumanth K Reddy; Francesco Federico Journal: J Atheroscler Thromb Date: 2013-09-11 Impact factor: 4.928
Authors: David S Liebeskind; George A Cotsonis; Jeffrey L Saver; Michael J Lynn; Tanya N Turan; Harry J Cloft; Marc I Chimowitz Journal: Ann Neurol Date: 2011-03-17 Impact factor: 10.422
Authors: Colin P Derdeyn; Tom O Videen; Kent D Yundt; Susanne M Fritsch; David A Carpenter; Robert L Grubb; William J Powers Journal: Brain Date: 2002-03 Impact factor: 13.501
Authors: Daniel M Mandell; Jay S Han; Julien Poublanc; Adrian P Crawley; Jeff A Stainsby; Joseph A Fisher; David J Mikulis Journal: Stroke Date: 2008-05-01 Impact factor: 7.914
Authors: Mark Jenkinson; Christian F Beckmann; Timothy E J Behrens; Mark W Woolrich; Stephen M Smith Journal: Neuroimage Date: 2011-09-16 Impact factor: 6.556
Authors: Richard G Wise; Kyle T S Pattinson; Daniel P Bulte; Peter A Chiarelli; Stephen D Mayhew; George M Balanos; David F O'Connor; Timothy R Pragnell; Peter A Robbins; Irene Tracey; Peter Jezzard Journal: J Cereb Blood Flow Metab Date: 2007-04-04 Impact factor: 6.200
Authors: A A Desai; M K Strother; C C Faraco; V L Morgan; T R Ladner; L M Dethrage; L C Jordan; M J Donahue Journal: AJNR Am J Neuroradiol Date: 2015-08-13 Impact factor: 3.825
Authors: Daniel F Arteaga; Megan K Strother; Carlos C Faraco; L Taylor Davis; Allison O Scott; Manus J Donahue Journal: J Magn Reson Imaging Date: 2019-04-02 Impact factor: 4.813
Authors: Carlos C Faraco; Megan K Strother; Jeroen C W Siero; Daniel F Arteaga; Allison O Scott; Lori C Jordan; Manus J Donahue Journal: J Cereb Blood Flow Metab Date: 2015-07-15 Impact factor: 6.200
Authors: Petrice M Cogswell; Taylor L Davis; Megan K Strother; Carlos C Faraco; Allison O Scott; Lori C Jordan; Matthew R Fusco; Blaise deB Frederick; Jeroen Hendrikse; Manus J Donahue Journal: J Magn Reson Imaging Date: 2017-01-06 Impact factor: 4.813
Authors: Sarah K Lants; Jennifer M Watchmaker; Meher R Juttukonda; Larry T Davis; Manus J Donahue; Matthew R Fusco Journal: World Neurosurg Date: 2017-12-20 Impact factor: 2.104
Authors: B A Roach; M J Donahue; L T Davis; C C Faraco; D Arteaga; S-C Chen; T R Ladner; A O Scott; M K Strother Journal: AJNR Am J Neuroradiol Date: 2016-04-07 Impact factor: 3.825